Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237572 · ClinicalTrials.gov registry record · Phase 1
Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
A Phase 1 study, sponsored by Patrick Dillon, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03237572 is a Phase 1 study that was terminated before completion, run by Patrick Dillon, MD. The registered enrollment target is 13 participants.
The verdict
NCT03237572, a Phase 1 study, was terminated before completion, sponsored by Patrick Dillon, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.
Interventions
- DRUG Pembrolizumab
- DEVICE High-intensity focused ultrasound (HIFU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2022-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237572
The ClinicalTrials.gov registry entry for NCT03237572 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Dillon, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03237572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03237572 about?
NCT03237572 is a clinical study titled "Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer". This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to r...
What is the current status of trial NCT03237572?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-09-25. Estimated completion is 2022-06-17.
What interventions are being tested in trial NCT03237572?
The interventions under investigation include: Pembrolizumab (DRUG), High-intensity focused ultrasound (HIFU) (DEVICE).
Who is sponsoring clinical trial NCT03237572?
This trial is sponsored by Patrick Dillon, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.